Key Highlights:
- Mankind Pharma has partnered with Denovo Sciences to launch an AI-led drug discovery program, combining Mankind’s R&D, experimental validation, and clinical development expertise with Denovo’s proprietary AI platform for molecular generation and prioritization.
- The collaboration will use a human-in-the-loop approach, where AI identifies and evaluates drug candidates while scientists validate and refine outcomes, aiming to shorten discovery timelines, improve lead quality, and accelerate the development of differentiated therapies.
- The partnership strengthens Mankind Pharma’s innovation strategy by integrating AI into its core R&D operations, while enabling Denovo Sciences to scale its AI-driven drug discovery platform through collaboration with a leading Indian pharmaceutical company.
Implications:
Mankind Pharma’s AI-led drug discovery partnership with Denovo Sciences strengthens its innovation agenda and adds another serious player to India’s emerging AI–pharma ecosystem, with a clear focus on faster, higher‑quality early discovery. By using a human‑in‑the‑loop model, Denovo’s platform generates and ranks molecular candidates while Mankind’s scientists validate and refine them, the collaboration aims to shorten discovery timelines and improve lead quality, which can ultimately expand Mankind’s pipeline of differentiated therapies and increase competitive pressure on peers that still rely on traditional discovery workflows.
Source: Denovo Sciences
